期刊论文详细信息
International Journal of Pediatric Endocrinology
Comparison of response to 2-years’ growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies
Henrik Thybo Christesen1  Birgitte Tønnes Pedersen6  Viatcheslav Rakov9  Marta Snajderova8  Judith Ross2  Oliver Blankenstein5  Maithé Tauber7  Isabelle Oliver7  Lars Sävendahl4  Peter A Lee3 
[1] H.C. Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark;Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA, USA;Penn State College of Medicine, The Milton S. Hershey Medical Center, PO Box 850, Hershey, PA, 17033-0850, USA;Division of Pediatric Endocrinology, Department of Women’s and Children´s Health, Karolinska Institutet, Stockholm, Sweden;Department of Pediatric Endocrinology, Charité-Universitätsmedizin Berlin, Berlin, Germany;Novo Nordisk A/S, Søborg, Denmark;Division of Pediatric Endocrinology, Hôpital des Enfants, Toulouse, France;Department of Pediatrics, 2nd Medical School - Charles University and University Hospital Motol, Prague, Czech Republic;Novo Nordisk Health Care AG, Zurich, Switzerland
关键词: Norditropin®;    Puberty;    Idiopathic short stature;    Multiple pituitary hormone deficiency;    Small for gestational age;    Isolated growth hormone deficiency;   
Others  :  813477
DOI  :  10.1186/1687-9856-2012-22
 received in 2012-05-08, accepted in 2012-06-23,  发布年份 2012
PDF
【 摘 要 】

Background

Few studies have compared the response to growth hormone (GH) treatment between indications such as isolated growth hormone deficiency (IGHD), born small for gestational age (SGA), idiopathic short stature (ISS), and multiple pituitary hormone deficiency (MPHD). The aim of this analysis of data, collected from two large ongoing observational outcome studies, was to evaluate growth and insulin-like growth factor-I (IGF-I) response data for children of short stature with IGHD, MPHD, SGA, or ISS following two years of treatment with the recombinant GH product Norditropin® (Novo Nordisk A/S, Bagsværd, Denmark).

Methods

Analysis of auxologic data from two ongoing prospective observational studies, NordiNet® International Outcomes Study (NordiNet® IOS) and NovoNet®/American Norditropin® Studies: Web-enabled Research (ANSWER) Program®.

Results

4,582 children aged <18 years were included: IGHD, n = 3,298; SGA, n = 678; ISS, n = 334; and MPHD, n = 272. After two years’ GH treatment, change in height standard deviation score (SDS) was +1.03 in SGA and +0.84 in ISS vs. +0.97 in IGHD (p = 0.047; p < 0.001 vs. IGHD, respectively). Height gain was comparable between IGHD and MPHD. In pre-pubertal children vs. total population, height SDS change after two years was: IGHD, +1.24 vs. +0.97; SGA, +1.17 vs. +1.03; ISS, +1.04 vs. +0.84; and MPHD, +1.16 vs. +0.99 (all p < 0.001).

Conclusions

After two years’ GH treatment, change in height SDS was greater in SGA and less in ISS, compared with IGHD; the discrepancy in responses may be due to the disease nature or confounders (i.e. age). Height SDS increase was greatest in pre-pubertal children, supporting early treatment initiation to optimize growth outcomes.

【 授权许可】

   
2012 Lee et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140710004249792.pdf 540KB PDF download
Figure 2. 26KB Image download
Figure 1. 38KB Image download
【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】
  • [1]Gharib H, Cook DM, Saenger PH, et al.: American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children – 2003 update. Endocr Pract 2003, 9(1):64-76.
  • [2]Cohen P, Rogol AD, Deal CL, et al.: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008, 93(11):4210-4217.
  • [3]Carel JC, Ecosse E, Nicolino M, et al.: Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry. Br Med J 2002, 325(7355):70.
  • [4]Takeda A, Cooper K, Bird A, et al.: Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 2010, 14(42):1-209. iii–iv
  • [5]Maghnie M, Ambrosini L, Cappa M, et al.: Adult height in patients with permanent growth hormone deficiency with and without multiple pituitary hormone deficiencies. J Clin Endocrinol Metab 2006, 91(8):2900-2905.
  • [6]Bannink E, Djurhuus CB, Christensen T, et al.: Adult height and health-related quality of life after growth hormone therapy in small for gestational age subjects. J Med Econ 2010, 13(2):221-227.
  • [7]Bryant J, Baxter L, Cave CB, Milne R: Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev 2007, 18(3):CD004440.
  • [8]Albertsson-Wikland K, Aronson AS, Gustafsson J, et al.: Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab 2008, 93(11):4342-4350.
  • [9]Dahlgren J, Wikland KA, Swedish Study Group for Growth Hormone Treatment: Final height in short children born small for gestational age treated with growth hormone. Pediatr Res 2005, 57(2):216-222.
  • [10]Thomas M, Massa G, Bourguignon JP, et al.: Final height in children with idiopathic growth hormone deficiency treated with recombinant human growth hormone: the Belgian experience. Horm Res 2001, 55(2):88-94.
  • [11]Maiorana A, Cianfarani S: Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics 2009, 124(3):e519-e531.
  • [12]Van Pareren Y, Mulder P, Houdijk M, et al.: Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose–response GH trial. J Clin Endocrinol Metab 2003, 88(8):3584-3590.
  • [13]Reiter EO, Price DA, Wilton P, et al.: Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006, 91(6):2047-2054.
  • [14]Rappaport R, Mugnier E, Limoni C, French Serono Study Group: A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. J Clin Endocrinol Metab 1997, 82(2):452-456.
  • [15]Cohen P, Germak J, Rogol AD, et al.: Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab 2010, 95(5):2089-2098.
  • [16]Högler W, Briody J, Moore B, et al.: Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency. Bone 2005, 37(5):642-650.
  • [17]Centers for Disease Control and Prevention: Percentile data files with LMS values. , ; . http://www.cdc.gov/growthcharts/percentile_data_files.htm webcite. Accessed 16 December 2010
  • [18]Brabant G, von zur Mühlen A, Wüster C, et al.: Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003, 60(2):53-60.
  • [19]Ross J, Lee PA, Gut R, Germak J: Factors influencing the one- and two-year growth response in children treated with growth hormone: analysis from an observational study. Int J Pediatr Endocrinol. 2010, 2010:494656. BioMed Central Full Text
  • [20]Bakker B, Frane J, Anhalt H, et al.: Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008, 93(2):352-357.
  • [21]Ranke MB, Lindberg A, Price DA, et al.: Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res 2007, 68(2):53-62.
  • [22]Clayton PE, Cianfarani S, Czernichow P, et al.: Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007, 92(3):804-810.
  • [23]Ranke MB, Lindberg A, Ferrández Longás A, et al.: Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatr Res 2007, 61(1):105-110.
  • [24]de Ridder MA, Stijnen T, Hokken-Koelega AC: Prediction model for adult height of small for gestational age children at the start of growth hormone treatment. J Clin Endocrinol Metab 2008, 93(2):477-483.
  • [25]Soriano-Guillen L, Coste J, Ecosse E, et al.: Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab 2005, 90(9):5197-5204.
  • [26]Cohen P, Rogol AD, Howard CP, et al.: Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007, 92(7):2480-2486.
  • [27]Wit JM, Clayton PE, Rogol AD, et al.: Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res 2008, 18(2):89-110.
  • [28]Bang P: Principles of growth hormone and insulin-like growth factor-I treatment in children with idiopathic short stature. Horm Res Paediatr 2011, 76(Suppl 3):24-26.
  • [29]Wilson TA, Rose SR, Cohen P, et al.: Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003, 143(4):415-421.
  • [30]Romano AA, Dana K, Bakker B, et al.: Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone. J Clin Endocrinol Metab 2009, 94(7):2338-2344.
  • [31]Bell J, Parker KL, Swinford RD, et al.: Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010, 95(1):167-177.
  文献评价指标  
  下载次数:14次 浏览次数:10次